三重激动剂 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-20. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
=== Cardiogenesis === Development of heart is involved in several rounds of EMT and MET. While development splanchnopleure undergo EMT and produce endothelial progenitors, these then form the endocardium through MET. Pericardium is formed by sinus venosus mesenchymal cells that undergo MET. Quite similar processes occur also while regeneration in the injured heart. Injured pericardium undergoes EMT and is transformed into adipocytes or myofibroblasts which induce arrhythmia and scars. MET than leads to the formation of vascular and epithelial progenitors that can differentiate into vasculogenic cells which lead to regeneration of heart injury.
== ST == st – (s) Sotho language (ISO 639-1 code) ST (s) Saint Lucia (FIPS 10-4 country code) São Tomé and Príncipe (ISO 3166 digram) STA (i) Scheduled Time of Arrival Surveillance and Target Acquisition STAGE – (a) Scenario Toolkit And Generation Environment STANAG – (p) (NATO) Standardisation Agreement STAR (a) Scientific and Technical Aerospace Reports (NASA) Simulation of Tactical Alternative Responses Special Threat Analysis and Recognition STAT (a) Signal Transducers and Activators of Transcription (cell biology) Special Tertiary Admissions Test (Australia) STB - Surface Transportation Board STC – (i) Superior Temporal Cortex S&TCD – (i) CERDEC Space and Terrestrial Communications Directorate STD (s) São Tomé and Príncipe dobra (ISO 4217 currency code) (i) Sexually Transmitted Disease STDM – (i) Statistical Time Division Multiplexing STEM (a) Scanning transmission electron microscopy Science, technology, engineering, and mathematics (p) Spatiaotemporal Epidemiological Modeler (IBM-developed software) STENTOR – (p) Satellite de télécommunications pour expérimenter de nouvelles technologies en orbite (French, "Orbital New Technology Experimental Telecommunications Satellite") STFU (i) Southern Tenant Farmers Union Stuff You "Shut the fuck up!" STH – Sonic the Hedgehog STI (i) Sexually Transmitted Infection Subaru Tecnica International STK – (i) Satellite Tool Kit STM – (i) Short Term Memory STOL – (i) Short Take-Off and Landing STOVL – (i) Short Take-Off and Vertical Landing STP (s) São Tomé and Príncipe (ISO 3166 trigram) (i) Standard Temperature and Pressure STR – (i) Short Tandem Repeat (DNA analysis) STRATCOM – (p) United States Strategic Command STRICOM (p) U.S. Army Simulation, Training & Instrumentation Command (1992–) Strike Command (1962–1971) STRIVE – (a) Synthetic Tactical Real-time Interactive Virtual Environment STSM – (i) Senior Technical Staff Member Stuka – (p) Sturzkampfflugzeug (German WWII dive bomber)
=== Places of worship === There are three Church of England churches in Wilmslow: St Bartholomew's, St Anne's and St John's. St Bartholomew's is a 16th-century building, which was modified in the 19th century; it has a turreted bell tower. The first rector of the church was a Thomas Dale, who is buried beneath a headstone presumably engraved by him outside the entrance to the church. Wilmslow Methodist Church occupies a modern building close to the town centre, replacing an 1886 building which itself replaced the original 1798 church, built seven years after John Wesley's death. The Sacred Heart & St Teresa's Church is the Roman Catholic church and dates from the late 19th century. Dean Row Chapel, 2 miles (3.2 km) east of the town centre, is a Grade II* listed building built around the end of the 17th century. Initially Presbyterian, it is now a Unitarian chapel. There is also a United Reformed Church in Wilmslow, close to the town centre.
Sources: en.wikipedia.org
Organisms have thousands of genes, and in sexually reproducing organisms these genes generally assort independently of each other. This means that the inheritance of an allele for yellow or green pea color is unrelated to the inheritance of alleles for white or purple flowers. This phenomenon, known as "Mendel's law of independent assortment, means that the alleles of different genes get shuffled between parents to form offspring with many different combinations. Different genes often interact to influence the same trait. In the Blue-eyed Mary (Omphalodes verna), for example, there exists a gene with alleles that determine the color of flowers: blue or magenta. Another gene, however, controls whether the flowers have color at all or are white. When a plant has two copies of this white allele, its flowers are white—regardless of whether the first gene has blue or magenta alleles. This interaction between genes is called epistasis, with the second gene epistatic to the first. Many traits are not discrete features (e.g. purple or white flowers) but are instead continuous features (e.g. human height and skin color). These complex traits are products of many genes. The influence of these genes is mediated, to varying degrees, by the environment an organism has experienced. The degree to which an organism's genes contribute to a complex trait is called heritability. Measurement of the heritability of a trait is relative—in a more variable environment, the environment has a bigger influence on the total variation of the trait.
In the conflict's early months it appeared that Gaddafi's government—with its greater fire-power—would be victorious. Both sides disregarded the laws of war, committing human rights abuses, including arbitrary arrests, torture, extrajudicial executions, and revenge attacks. On 26 February, the United Nations Security Council passed Resolution 1970, suspending Libya from the UN Human Rights Council, implementing sanctions and calling for an International Criminal Court (ICC) investigation into the killing of unarmed civilians. In March, the Security Council declared a no-fly zone to protect the civilian population from aerial bombardment, calling on foreign nations to enforce it; it also specifically prohibited foreign occupation. Ignoring this, Qatar sent hundreds of troops to support the dissidents and, along with France and the United Arab Emirates, provided weaponry and military training to the NTC. NATO announced that it would enforce the no-fly zone. On 30 April a NATO airstrike killed Gaddafi's sixth son and three of his grandsons in Tripoli. This Western military intervention was criticized by various leftist governments, including those that had criticized Gaddafi's response to the protests, because they regarded it as an imperialist attempt to secure control of Libya's resources. In June, the ICC issued arrest warrants for Gaddafi, his son Saif al-Islam, and his brother-in-law Abdullah Senussi, head of state security, for charges concerning crimes against humanity.
== Q == Juda Hirsch Quastel FRS (1899–1987). British-Canadian biochemist at the Rothamsted Experimental Station and McGill University, known for research in neurochemistry, metabolism and cancer. Osbourne Quaye. Ghanaian biochemist
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。